These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34652527)

  • 1. Left atrial appendage closure with the watchman device reduces atrial fibrillation management costs.
    D Ancona G; Safak E; Weber D; Arslan F; Kische S; Darius H; Behrens S; Zohlenhöfer-Momm D; Ortak J; Kugler J; Ince H
    Clin Res Cardiol; 2022 Jan; 111(1):105-113. PubMed ID: 34652527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Actual management costs of patients with non-valvular atrial fibrillation treated with percutaneous left atrial appendage closure or oral anticoagulation.
    D'Ancona G; Arslan F; Safak E; Weber D; Al Ammareen R; Ince H
    Int J Cardiol; 2022 Mar; 351():61-64. PubMed ID: 34929249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of left atrial appendage closure in non-valvular atrial fibrillation in patients over 75 years.
    Yu J; Chen H; Post F; Muenzel M; Keil T; Hou CR; Zhao M; Meng Z; Jiang L
    Heart Vessels; 2019 Nov; 34(11):1858-1865. PubMed ID: 31144099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation.
    Osmancik P; Herman D; Neuzil P; Hala P; Taborsky M; Kala P; Poloczek M; Stasek J; Haman L; Branny M; Chovancik J; Cervinka P; Holy J; Kovarnik T; Zemanek D; Havranek S; Vancura V; Opatrny J; Peichl P; Tousek P; Lekesova V; Jarkovsky J; Novackova M; Benesova K; Widimsky P; Reddy VY;
    J Am Coll Cardiol; 2020 Jun; 75(25):3122-3135. PubMed ID: 32586585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining Watchman left atrial appendage closure and catheter ablation for atrial fibrillation: multicentre registry results of feasibility and safety during implant and 30 days follow-up.
    Phillips KP; Pokushalov E; Romanov A; Artemenko S; Folkeringa RJ; Szili-Torok T; Senatore G; Stein KM; Razali O; Gordon N; Boersma LVA
    Europace; 2018 Jun; 20(6):949-955. PubMed ID: 29106523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials.
    Reddy VY; Doshi SK; Kar S; Gibson DN; Price MJ; Huber K; Horton RP; Buchbinder M; Neuzil P; Gordon NT; Holmes DR;
    J Am Coll Cardiol; 2017 Dec; 70(24):2964-2975. PubMed ID: 29103847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Safety and Efficacy in Continued Access Left Atrial Appendage Closure Registries.
    Holmes DR; Reddy VY; Gordon NT; Delurgio D; Doshi SK; Desai AJ; Stone JE; Kar S
    J Am Coll Cardiol; 2019 Dec; 74(23):2878-2889. PubMed ID: 31806131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of combined catheter ablation and left atrial appendage closure for symptomatic atrial fibrillation in patients with high stroke and bleeding risk.
    Kawakami H; Nolan MT; Phillips K; Scuffham PA; Marwick TH
    Am Heart J; 2021 Jan; 231():110-120. PubMed ID: 32822655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Results of Left Atrial Appendage Closure with Watchman Device in Patients with Atrial Fibrillation.
    Pheerawong P; Songmuang SB; Lertsuwunseri V; Satitthummanid S; Srimahachota S
    J Med Assoc Thai; 2015 Oct; 98(10):942-9. PubMed ID: 26638585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The budget impact of left atrial appendage closure compared with adjusted-dose warfarin and dabigatran etexilate for stroke prevention in atrial fibrillation.
    Amorosi SL; Armstrong S; Da Deppo L; Garfield S; Stein K
    Europace; 2014 Aug; 16(8):1131-6. PubMed ID: 24687964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Left atrial appendage closure with the Watchman device using intracardiac vs transesophageal echocardiography: Procedural and cost considerations.
    Hemam ME; Kuroki K; Schurmann PA; Dave AS; Rodríguez DA; Sáenz LC; Reddy VY; Valderrábano M
    Heart Rhythm; 2019 Mar; 16(3):334-342. PubMed ID: 30827462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes and costs of left atrial appendage closure from randomized controlled trial and real-world experience relative to oral anticoagulation.
    Panikker S; Lord J; Jarman JW; Armstrong S; Jones DG; Haldar S; Butcher C; Khan H; Mantziari L; Nicol E; Hussain W; Clague JR; Foran JP; Markides V; Wong T
    Eur Heart J; 2016 Dec; 37(46):3470-3482. PubMed ID: 26935273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review on left atrial appendage closure with the LAmbre device in patients with non-valvular atrial fibrillation.
    Ali M; Rigopoulos AG; Mammadov M; Torky A; Auer A; Matiakis M; Abate E; Bakogiannis C; Tzikas S; Bigalke B; Sedding D; Noutsias M
    BMC Cardiovasc Disord; 2020 Feb; 20(1):78. PubMed ID: 32050904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary and Secondary Stroke Prevention Using Left Atrial Appendage Closure with Watchman Devices in Atrial Fibrillation Patients: A Single Center Experience from Mainland China.
    Chen Y; Zhang Y; Huang W; Huang K; Xu B; Su XI
    Pacing Clin Electrophysiol; 2017 Jun; 40(6):607-614. PubMed ID: 28084014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin.
    Reddy VY; Akehurst RL; Armstrong SO; Amorosi SL; Brereton N; Hertz DS; Holmes DR
    Europace; 2016 Jul; 18(7):979-86. PubMed ID: 26838691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of chronic kidney disease on Watchman implantation: experience with 300 consecutive left atrial appendage closures at a single center.
    Xue X; Jiang L; Duenninger E; Muenzel M; Guan S; Fazakas A; Cheng F; Illnitzky J; Keil T; Yu J
    Heart Vessels; 2018 Sep; 33(9):1068-1075. PubMed ID: 29564543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and Predictors of Clinically Significant Bleedings after Transcatheter Left Atrial Appendage Closure.
    Zieliński K; Pracoń R; Konka M; Kruk M; Kępka C; Trochimiuk P; Dębski M; Kaczmarska E; Przyłuski J; Kowalik I; Dzielińska Z; Kurowski A; Witkowski A; Demkow M
    Int J Environ Res Public Health; 2022 Oct; 19(21):. PubMed ID: 36360682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation.
    Reddy VY; Akehurst RL; Amorosi SL; Gavaghan MB; Hertz DS; Holmes DR
    Stroke; 2018 Jun; 49(6):1464-1470. PubMed ID: 29739915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Percutaneous left atrial appendage closure reduces cost of care independent of the institutional cumulative caseload in patients with non-valvular atrial fibrillation.
    D'Ancona G; Arslan F; Safak E; Weber D; Ince H
    Neth Heart J; 2022 Oct; 30(10):481-485. PubMed ID: 35352274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined atrial fibrillation ablation and left atrial appendage closure: long-term follow-up from a large multicentre registry.
    Wintgens L; Romanov A; Phillips K; Ballesteros G; Swaans M; Folkeringa R; Garcia-Bolao I; Pokushalov E; Boersma L
    Europace; 2018 Nov; 20(11):1783-1789. PubMed ID: 29547906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.